{"publication_id":"04a4e243-1f41-43e8-9394-cf52f62997db","content_hash":"sha256:904b8a4497a737a44048387e12acc690a9190837d3c8506fc669057ffb9b2b29","nodes":[{"id":"04a4e243-1f41-43e8-9394-cf52f62997db","type":"publication","title":"Research Synthesis: Metformin Treatment Effects — full paper"},{"id":"claim_1","type":"claim","text":"This paper synthesizes evidence on metformin treatment effects across 56 accepted source papers and 3357 high-confidence extracted claims."},{"id":"claim_2","type":"claim","text":"The evidence profile contains 6 direct clinical sources, 27 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 484 cross-study disagreements across the evidence base."},{"id":"claim_3","type":"claim","text":"Positive study-level signals are summarized in the cardiometabolic and contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes, and negative signals in the cardiometabolic, contextual adjacent evidence, safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_4","type":"claim","text":"The conclusion is that metformin treatment effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_5","type":"claim","text":"This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_treatment_effects-v06-DAILY-2026-06-12T04-21-22Z-R2`."},{"id":"claim_6","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_7","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_8","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, dosing and pharmacokinetics, immune and inflammation, longevity, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_9","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_10","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_11","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_12","type":"claim","text":"| Contextual Adjacent Evidence | n=27; claims=1160 | no extracted directional signal in 18/27 sources | 1 direct; 16 indirect; 10 review | limited corpus depth in this outcome class |"},{"id":"claim_13","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_14","type":"claim","text":"27 included sources were assigned to this outcome class. Directional coding: negative=1, null=18, positive=1, unclear=7. Directness coding: direct=1, indirect=16, review=10."},{"id":"claim_15","type":"claim","text":"18 included sources were assigned to this outcome class. Directional coding: mixed=3, negative=4, null=7, positive=2, unclear=2. Directness coding: direct=5, indirect=6, review=7."},{"id":"claim_16","type":"claim","text":"3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=1, review=2."},{"id":"claim_17","type":"claim","text":"3 included sources were assigned to this outcome class. Directional coding: negative=1, null=2. Directness coding: indirect=2, review=1."},{"id":"claim_18","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1."},{"id":"claim_19","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_20","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_21","type":"claim","text":"The curated corpus is dominated by sources in which metformin is used as background or add-on therapy rather than as the randomized intervention under test, and this constrains what the headline conclusions can support. In Hong 2026, Seo 2026, Lee 2026, Lim 2026, Zaveri 2026, Mohan 2026, and Kim 2026, metformin is the comparator floor or backbone to which a new agent (pioglitazone 30 mg, lobeglitazone 0.5 mg, empagliflozin, sitagliptin+empagliflozin FDC, sitagliptin+glimepiride FDC, glimepiride+voglibose, or a fourth oral drug) is added. Across those records, between-group p-values are routinely <0.0001 or <0.001, but the contrast is rarely metformin-vs-placebo. Conclusions about metformin monotherapy efficacy and durability therefore rest on indirect inference, not on within-corpus metformin-vs-placebo arms. The single RCT that randomizes metformin vs another glucose-lowering agent head-to-head in this bundle is Lim 2026b (empagliflozin vs metformin in drug-naïve T2D, HbA1c change −0.78% on metformin), and that single source is the only one that anchors a direct monotherapy estimate in the corpus."},{"id":"claim_22","type":"claim","text":"For metformin treatment effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_23","type":"claim","text":"This synthesis maps 56 included sources on Metformin Treatment Effects across 9 outcome classes and 484 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_24","type":"claim","text":"Across 56 curated reference papers, the evidence base for Metformin Treatment Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Metformin Treatment Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_25","type":"claim","text":"Prior reviews in the corpus (Malik 2026, Hamsho 2026, Zhang 2026, Lim 2026b, Kao 2026) emphasize convergent signals on Metformin Treatment Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"claim_26","type":"claim","text":"| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |"},{"id":"claim_27","type":"claim","text":"| cardiometabolic | 5 | 13 | mixed, negative, null, positive, unclear | conflict-resolution gap |"},{"id":"claim_28","type":"claim","text":"| dosing and pharmacokinetics | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |"},{"id":"claim_29","type":"claim","text":"| safety and comorbidity | 0 | 3 | negative, null | direct interventional hard-endpoint gap |"},{"id":"claim_30","type":"claim","text":"| skeletal, fracture, and bone | 0 | 1 | null | direct interventional hard-endpoint gap |"},{"id":"source_1","type":"source","study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","year":2026,"doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","year":2026,"doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","year":2026,"doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","year":2026,"doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","year":2026,"doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis","year":2026,"doi":"10.1097/MD.0000000000049050","url":"https://doi.org/10.1097/MD.0000000000049050","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_7","type":"source","study":"Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study","year":2026,"doi":"10.1111/dom.70778","url":"https://doi.org/10.1111/dom.70778","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_8","type":"source","study":"Efficacy and Safety of Fixed‐Dose Combinations of Sitagliptin and Empagliflozin as Add‐On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Multi‐Centre, Placebo‐Controlled, Phase III Trial","year":2026,"doi":"10.1111/dom.70669","url":"https://doi.org/10.1111/dom.70669","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_9","type":"source","study":"Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study","year":2026,"doi":"10.1111/1753-0407.70217","url":"https://doi.org/10.1111/1753-0407.70217","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_10","type":"source","study":"Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome","year":2026,"doi":"10.1111/dom.70478","url":"https://doi.org/10.1111/dom.70478","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_11","type":"source","study":"Associations of modifiable preconception, pregnancy and postpartum factors with health outcomes for women with type 2 diabetes and their children: A systematic review and meta‐analysis of observational studies","year":2026,"doi":"10.1111/dme.70183","url":"https://doi.org/10.1111/dme.70183","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_12","type":"source","study":"Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta‐Analysis","year":2026,"doi":"10.1002/edm2.70238","url":"https://doi.org/10.1002/edm2.70238","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_13","type":"source","study":"Impact of metformin on melanoma: a meta-analysis and systematic review","year":2024,"doi":"10.3389/fonc.2024.1399693","url":"https://doi.org/10.3389/fonc.2024.1399693","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_14","type":"source","study":"Effects of probiotic and metformin co-administration versus metformin monotherapy on anthropometric measurements, hormones, and glucolipid profile in women with polycystic ovary syndrome: a systematic review and meta-analysis","year":2026,"doi":"10.3389/fendo.2026.1802369","url":"https://doi.org/10.3389/fendo.2026.1802369","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_15","type":"source","study":"EMERGE Mothers and Kids: a longitudinal cohort study of mothers and children enrolled in the randomized placebo-controlled trial of metformin in women with GDM (EMERGE): study protocol","year":2026,"doi":"10.1186/s13063-026-09703-6","url":"https://doi.org/10.1186/s13063-026-09703-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_16","type":"source","study":"Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis","year":2026,"doi":"10.3389/fendo.2026.1815219","url":"https://doi.org/10.3389/fendo.2026.1815219","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_17","type":"source","study":"Effectiveness and safety of auricular therapy for polycystic ovary syndrome: a systematic review and meta-analysis","year":2026,"doi":"10.3389/fendo.2026.1726938","url":"https://doi.org/10.3389/fendo.2026.1726938","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_18","type":"source","study":"Metformin increases glycolysis and the stress-induced cytokine GDF15 but not FGF21 in humans","year":2026,"doi":"10.3389/fendo.2026.1797525","url":"https://doi.org/10.3389/fendo.2026.1797525","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_19","type":"source","study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","year":2026,"doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_20","type":"source","study":"Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial","year":2026,"doi":"10.1186/s12933-026-03142-y","url":"https://doi.org/10.1186/s12933-026-03142-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_21","type":"source","study":"Metformin for primary prevention of colorectal neoplasms in adenoma-free populations: a systematic review and dose-response meta-analysis","year":2025,"doi":"10.3389/fphar.2025.1645387","url":"https://doi.org/10.3389/fphar.2025.1645387","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_22","type":"source","study":"Multi-strain probiotic reduces gastrointestinal side effects in women with elevated HOMA-IR index treated with metformin: a 12-week randomised controlled trial","year":2026,"doi":"10.3389/fendo.2026.1765741","url":"https://doi.org/10.3389/fendo.2026.1765741","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_23","type":"source","study":"Efficacy and safety of traditional Chinese classic prescriptions combined with metformin in the treatment of type 2 diabetes mellitus: a Bayesian network meta-analysis","year":2026,"doi":"10.3389/fphar.2026.1693378","url":"https://doi.org/10.3389/fphar.2026.1693378","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_24","type":"source","study":"The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes—secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE)","year":2026,"doi":"10.1186/s12916-026-04778-z","url":"https://doi.org/10.1186/s12916-026-04778-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_25","type":"source","study":"Effects of Premeal Versus Postmeal Metformin Administration on Postmeal Glycemic Control in Individuals With Type 2 Diabetes Mellitus: A Randomized, 8‐Week Crossover Study","year":2026,"doi":"10.1111/dom.70768","url":"https://doi.org/10.1111/dom.70768","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_26","type":"source","study":"The Impact of Metformin on Vitamin B12 Levels in Children and Adolescents: A Systematic Review and Single‐Arm Meta‐Analysis","year":2026,"doi":"10.1002/edm2.70232","url":"https://doi.org/10.1002/edm2.70232","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_27","type":"source","study":"Metformin safety during pregnancy in women with gestational diabetes mellitus: A systematic review and meta‐analysis of maternal, neonatal and long‐term outcomes","year":2025,"doi":"10.1111/dme.70173","url":"https://doi.org/10.1111/dme.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_28","type":"source","study":"The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study","year":2026,"doi":"10.1155/jdr/9957473","url":"https://doi.org/10.1155/jdr/9957473","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_29","type":"source","study":"Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP ‐ ELM study","year":2026,"doi":"10.1111/jdi.70245","url":"https://doi.org/10.1111/jdi.70245","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_30","type":"source","study":"Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial","year":2026,"doi":"10.1136/bmjopen-2025-115656","url":"https://doi.org/10.1136/bmjopen-2025-115656","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_31","type":"source","study":"SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register‐based randomised trial on prevention of diabetic complications","year":2025,"doi":"10.1111/dom.70320","url":"https://doi.org/10.1111/dom.70320","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_32","type":"source","study":"Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin (850/50mg) in healthy Tunisian subjects under fed conditions","year":2026,"doi":"10.1038/s41598-025-34082-4","url":"https://doi.org/10.1038/s41598-025-34082-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_33","type":"source","study":"Efficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials","year":2026,"doi":"10.3389/fphar.2026.1752095","url":"https://doi.org/10.3389/fphar.2026.1752095","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_34","type":"source","study":"Applying a hypothetical strategy to the intercurrent event of non-adherence with the parametric g-formula: a post hoc secondary analysis of the MET-PREVENT randomised controlled trial","year":2026,"doi":"10.1186/s13063-026-09708-1","url":"https://doi.org/10.1186/s13063-026-09708-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_35","type":"source","study":"Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis","year":2025,"doi":"10.1158/1940-6207.CAPR-25-0104","url":"https://doi.org/10.1158/1940-6207.CAPR-25-0104","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_36","type":"source","study":"Metformin Use and Clinical Outcomes in Very Elderly Patients with Type 2 Diabetes and Chronic Kidney Disease","year":2026,"doi":"10.3390/medicina62040776","url":"https://doi.org/10.3390/medicina62040776","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_37","type":"source","study":"The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis","year":2026,"doi":"10.3389/fendo.2026.1780676","url":"https://doi.org/10.3389/fendo.2026.1780676","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_38","type":"source","study":"MET-PREVENT: metformin to improve physical performance in older people with sarcopenia and physical prefrailty/frailty – protocol for a double-blind, randomised controlled proof-of-concept trial","year":2022,"doi":"10.1136/bmjopen-2022-061823","url":"https://doi.org/10.1136/bmjopen-2022-061823","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_39","type":"source","study":"Disuse‐induced muscle fibrosis, cellular senescence, and senescence‐associated secretory phenotype in older adults are alleviated during re‐ambulation with metformin pre‐treatment","year":2023,"doi":"10.1111/acel.13936","url":"https://doi.org/10.1111/acel.13936","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_40","type":"source","study":"Circulating Profiles of the Bile Acid Metabolomics in Patients With Polycystic Ovary Syndrome Treated With Metformin or Canagliflozin","year":2026,"doi":"10.1002/phar.70092","url":"https://doi.org/10.1002/phar.70092","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_41","type":"source","study":"Paternal use of metformin and risk of major congenital malformations: A meta‐analysis of 4 studies","year":2026,"doi":"10.1002/bcp.70547","url":"https://doi.org/10.1002/bcp.70547","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_42","type":"source","study":"Effects of Ziziphus jujuba, metformin, and myoinositol on pregnancy rates and metabolic parameters in infertile women with PCOS: a randomized controlled trial","year":2026,"doi":"10.1186/s13048-025-01867-0","url":"https://doi.org/10.1186/s13048-025-01867-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_43","type":"source","study":"Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial","year":2025,"doi":"10.1002/hon.70163","url":"https://doi.org/10.1002/hon.70163","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_44","type":"source","study":"Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial.","year":2026,"doi":"10.1111/dom.70527","url":"https://doi.org/10.1111/dom.70527","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_45","type":"source","study":"Comparative Efficacy, Safety, and Cost‐Utility of DPP‐4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real‐World Clinical and Economic Outcomes","year":2026,"doi":"10.1155/jdr/8464330","url":"https://doi.org/10.1155/jdr/8464330","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_46","type":"source","study":"Metformin for asthma exacerbations","year":2026,"doi":"10.1002/14651858.CD016177","url":"https://doi.org/10.1002/14651858.CD016177","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_47","type":"source","study":"Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study.","year":2026,"doi":"10.1016/j.jdiacomp.2025.109214","url":"https://doi.org/10.1016/j.jdiacomp.2025.109214","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_48","type":"source","study":"Randomized controlled trial of effects of metformin in NAFLD patients with newly diagnosed type 2 diabetes treated with an intensive lifestyle: a study protocol","year":2025,"doi":"10.1186/s13063-025-09191-0","url":"https://doi.org/10.1186/s13063-025-09191-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_49","type":"source","study":"The efficacy of metformin for pain, function, and quality of life in knee osteoarthritis: A systematic review and meta-analysis.","year":2026,"doi":"10.1016/j.semarthrit.2025.152908","url":"https://doi.org/10.1016/j.semarthrit.2025.152908","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_50","type":"source","study":"Metformin for knee osteoarthritis in overweight and obese adults: a systematic review and meta-analysis of efficacy, safety, and disease-modifying anti-inflammatory potential.","year":2026,"doi":"10.1007/s10787-026-02218-1","url":"https://doi.org/10.1007/s10787-026-02218-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_51","type":"source","study":"Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients","year":2035,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_52","type":"source","study":"The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists","year":2026,"doi":"10.3390/ijms27093967","url":"https://doi.org/10.3390/ijms27093967","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_53","type":"source","study":"Association between preoperative metformin exposure and postoperative nausea and vomiting in patients undergoing general anaesthesia: a protocol for a prospective observational cohort study in a Chinese tertiary hospital","year":2026,"doi":"10.1136/bmjopen-2026-117537","url":"https://doi.org/10.1136/bmjopen-2026-117537","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_54","type":"source","study":"Effectiveness of metformin in the management of osteoarthritis in patients with type 2 diabetes.","year":2026,"doi":"10.1007/s10067-026-07970-x","url":"https://doi.org/10.1007/s10067-026-07970-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_55","type":"source","study":"The mechanisms of action of metformin","year":2017,"doi":"10.1007/s00125-017-4342-z","url":"https://doi.org/10.1007/s00125-017-4342-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_56","type":"source","study":"Metformin and the gastrointestinal tract","year":2016,"doi":"10.1007/s00125-015-3844-9","url":"https://doi.org/10.1007/s00125-015-3844-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_57","type":"source","study":"**Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.","year":2005,"doi":"10.1371/journal.pmed.0020124","url":"https://doi.org/10.1371/journal.pmed.0020124","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_58","type":"source","study":"**ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.","year":2024,"doi":"10.2337/dc24-s006","url":"https://doi.org/10.2337/dc24-s006","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_59","type":"source","study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_60","type":"source","study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_61","type":"source","study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_62","type":"source","study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_63","type":"source","study":"Pragmatic 2035","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_1","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_2","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_3","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_4","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_5","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_6","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_7","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_8","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_9","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_10","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_11","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_12","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_13","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_14","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_15","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_16","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_17","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_18","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_19","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_20","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_21","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_22","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_23","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_24","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_25","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_26","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_27","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_28","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_29","type":"contains_claim"},{"from":"04a4e243-1f41-43e8-9394-cf52f62997db","to":"claim_30","type":"contains_claim"}],"screening":{"identified":59,"screened":59,"excluded":0,"included":59,"included_or_retained":59,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"59 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}